Goldman Sachs Group Inc Global Blood Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$32.4 - $68.18 $33.5 Million - $70.5 Million	1,033,433 Added 153.52%	1,706,600 $116 Million
Q3 2022 Nov 10, 2022	BUY	$32.4 - $68.18 $33.5 Million - $70.5 Million	1,033,433 Added 153.52%	1,706,600 $116 Million
Q2 2022 May 14, 2024	BUY	$22.3 - $37.39 $15 Million - $25.2 Million	673,167 New	673,167 $21.5 Million
Q2 2022 Aug 15, 2022	SELL	$22.3 - $37.39 $25.9 Million - $43.4 Million	-1,160,553 Reduced 63.29%	673,167 $21.5 Million
Q1 2022 May 16, 2022	BUY	$25.68 - $35.59 $15.3 Million - $21.2 Million	595,983 Added 48.15%	1,833,720 $63.5 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $11.5 Million - $18.6 Million	461,580 Added 59.47%	1,237,737 $36.2 Million
Q3 2021 Nov 10, 2021	BUY	$25.48 - $37.34 $19.8 Million - $29 Million	776,157 New	776,157 $19.8 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.